ScholarLens Back to search
2016•Journal of HepatologyRequires access

Antiviral Treatment in Patients with Advanced Hcv Cirrhosis Using Sofosbuvir and Ledipasvir/Daclatasvir with or without Ribavirin - 6 and 12 Month Outcomes Compared to Untreated Patients

Michelle C.M. Cheung, Graham R. Foster, William Lucien Irving, Alex J Walker, Ben Hudson, S. Verma, John McLauchlan, D.J. Mutimer, Andrew D. Brown, William Gelson, D. MacDonald, Kosh Agarwal

Open publisher page 7 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 7 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Daclatasvir, Sofosbuvir, Ledipasvir, Ribavirin, Medicine, Cirrhosis, Hepatitis C, Internal medicine

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
Antiviral Treatment in Patients with Advanced Hcv Cirrhosis Using Sofosbuvir and Ledipasvir/Daclatasvir with or without Ribavirin - 6 and 12 Month Outcomes Compared to Untreated Patients — Research Paper | ScholarLens